MedTrace Logo

Study of CIDP Patients During IVIG Treatment

NCT00305266 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2007-12-03

No results posted yet for this study

Summary

The aim of this study is to quantify the effect of IVIG treatment in a group of patients with chronic inflammatory demyelinating polyradiculoneuropathy(CIDP), who requires continues treatment of IVIG at regular intervals of 3-10 weeks:

1. During continues treatment of IVIG at regular intervals of 3-10 weeks.
2. During pause in treatment.

Hypothesis:

1. The disease activity in the patients are cyclical correlating to the treatment intervals.
2. Pause in treatment will increase disease activity, which can be quantified with symptom scores, disability scales, and clinical test.

Primary effect parameter is muscle strength quantified by isokinetic dynamometry.

Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.

Conditions

  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions

DRUG

intravenous gammaglobulin

individual dose

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henning Andersen, MD · Aarhus University Hospital

  • Johannes Jakobsen, professor · Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Completion
2007-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00305266 on ClinicalTrials.gov